Lantus is insulin glargine, a longer-acting product than regular insulin. Merck is hoping to bring MK-1293, its own insulin glargine treatment, to market with the help of its biosimilar drug partner. Phase III studies will begin soon, Merck said.
written on 10.02.2014
Merck collaborates with Samsung to develop copy of Sanofi's Lantus diabetes therapy